Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cediranib maleate
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
Durvalumab and Olaparib and/or Cediranib Maleate in Treating Patients with Advanced Solid Tumors or Recurrent Ovarian, Breast, Lung, Prostate, or Colorectal Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0145, NCI-2015-01401, P141726, NCT02484404
Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 8463, NCI-2013-01452, P09512, 090192, 09-C-0192, NCT00942877
Sunitinib Malate or Cediranib Maleate in Treating Patients with Metastatic Soft Tissue Sarcoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 20
Trial IDs: 8875, NCI-2013-01496, 110200, P11836, 11-C-0200, NCT01391962
Olaparib and Cediranib Maleate in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9825, NCI-2015-00051, 16-700, NCT02345265
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9881, NCI-2015-01097, 1604017576, NCT02498613
Olaparib with or without Cediranib in Treating Patients with Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9984, NCI-2016-01346, 2000020461, NCT02893917
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients with Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9974, NCI-2016-01363, NCT02899728
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D8488C00001, NCI-2016-01569, NCT02889900
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients with Recurrent Glioblastoma
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10067, NCI-2016-01769, NCT02974621
Start Over